Darbepoetin Alfa Reduces Red Blood Cell Transfusions In Patients With Myelodysplastic Syndrome

The results of a phase 3 trial indicate that darbepoetin alfa (Aranesp) reduces the incidence of red blood cell transfusions in anemic patients that have low and intermediate-1 risk myelodysplastic syndrome (MDS).1

MDS, a common adult bone marrow malady, occurs due to a failure of blood cells to mature inside the person's bone marrow. This results in a reduced number of healthy red and white blood cells and can render the body more vulnerable to infection, bleeding, or anemia. MDS can be caused as a side effect of radiotherapy or chemotherapy treatment for cancer. Approximately 30 000 people in the United States are affected by this syndrome each year.

This randomized, double-blind, placebo-controlled trail was conducted by Amgen. They reported that darbepoetin alfa improved erythroid response and that adverse events were balanced to the trial treatment arms. Adverse events seen more frequently with darbepoetin alfa included myalgia, fatigue, and pyrexia.

REFERENCE

1. Amgen. Phase 3 study demonstrates Aranesp® (darbepoetin alfa) reduces red blood cell transfusions in patients with myelodysplastic syndrome (MDS) [press release]. PR Newswire Web site. http://www.prnewswire.com/news-releases/phase-3-study-demonstrates-aranesp-darbepoetin-alfa-reduces-red-blood-cell-transfusions-in-patients-with-myelodysplastic-syndrome-mds-300220161.html. Dated February 15, 2016. Accessed February 16, 2016.

Loading links....
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs